DATASHEET
Host:
Rabbit
Target Protein:
PRKAR2A
Specificity:
KO-Validated
Immunogen Range:
1-404/404
Clonality:
Polyclonal
Isotype:
IgG
Entrez Gene:
5576
Swiss Prot:
P13861
Source:
Recombinant fusion protein containing a sequence corresponding to amino acids 1-404 of human PRKAR2A (NP_004148.1).
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Store at -20°C for 12 months.
Background:
cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. The protein encoded by this gene is one of the regulatory subunits. This subunit can be phosphorylated by the activated catalytic subunit. It may interact with various A-kinase anchoring proteins and determine the subcellular localization of cAMP-dependent protein kinase. This subunit has been shown to regulate protein transport from endosomes to the Golgi apparatus and further to the endoplasmic reticulum (ER).
VALIDATION IMAGES
Lane 1: Hela cell lysates; Lane 2: PRKAR2A knockout (KO) HeLa cell lysates probed with PRKAR2A Polyclonal Antibody, Unconjugated (bs-55176R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Hela cell lysates; Lane 2: Jurkat cell lysates; Lane 3: SW480 cell lysates; Lane 4: LO2 cell lysates; Lane 5: Mouse Lung lysates; Lane 6: Rat skeletal muscle lysates probed with PRKAR2A Polyclonal Antibody, Unconjugated (bs-55176R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.